🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Helen T. Chifotides

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0001-8044-4960

Materials ScienceMedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs”.

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

Blood Advances(2021)10.1182/bloodadvances.2020003934

N/A

0DataRank · unranked

48 citations

Courtney D. DiNardo, Prithviraj Bose, Naveen Pemmaraju, Naval Daver, Tapan M. Kadia +7 more

Accelerated Phase of Myeloproliferative Neoplasms

Acta Haematologica(2021)10.1159/000512929

N/A

0DataRank · unranked

41 citations

Helen T. Chifotides, Prithviraj Bose, Lucia Masárová, Srđan Verstovšek, Omar Shahin

Momelotinib: an emerging treatment for myelofibrosis patients with anemia

Journal of Hematology & Oncology(2022)10.1186/s13045-021-01157-4

N/A

0DataRank · unranked

89 citations

Prithviraj Bose, Srđan Verstovšek, Helen T. Chifotides

Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN

International review of cell and molecular biology(2022)10.1016/bs.ircmb.2021.02.008

N/A

0DataRank · unranked

19 citations

Helen T. Chifotides, Srđan Verstovšek, Prithviraj Bose, Sergiu Paşca

Characteristics of patients with myelofibrosis on ruxolitinib for three or more years.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e19082

N/A

0DataRank · unranked

0 citations

Prithviraj Bose, Naveen Pemmaraju, Helen T. Chifotides, Lingsha Zhou, Zeev Estrov +3 more

ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis

Cancers(2023)10.3390/cancers16010154

N/A

0DataRank · unranked

28 citations

Helen T. Chifotides, Sebastiano Giallongo, Cesarina Giallongo, Daniele Tibullo, Giuseppe A. Palumbo +1 more

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments

Cancers(2023)10.3390/cancers15133331

N/A

0DataRank · unranked

22 citations

Srđan Verstovšek, Prithviraj Bose, Helen T. Chifotides

SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis

Clinical Lymphoma Myeloma & Leukemia(2023)10.1016/j.clml.2022.12.014

N/A

0DataRank · unranked

8 citations

Lucia Masárová, Srđan Verstovšek, Helen T. Chifotides

Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes

Nature Communications(2024)10.1038/s41467-024-46424-3

N/A

0DataRank · unranked

10 citations

Irene Gañán‐Gómez, Feiyang Ma, Kelly S. Chien, Mónica Del Rey, Sanam Loghavi +13 more

SOHO State of the Art Update and Next Questions: Current and Emerging Therapies for Systemic Mastocytosis

Clinical Lymphoma Myeloma & Leukemia(2024)10.1016/j.clml.2024.06.005

N/A

0DataRank · unranked

6 citations

Prithviraj Bose, Helen T. Chifotides

Emerging Therapeutic Approaches for Anemia in Myelofibrosis

Current Hematologic Malignancy Reports(2025)10.1007/s11899-025-00751-4

N/A

0DataRank · unranked

4 citations

Andrea Duminuco, Elena Torre, Calogero Vetro, Patrick Harrington, Giuseppe A. Palumbo +2 more